AdamWaxmanMD

PubMed

• Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis.
  Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T Vogl, Mia Djulbegovic
  European Journal of Haematology. 2025-03-01
• Nontuberculous mycobacterial infections following teclistamab in multiple myeloma.
  Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi
  Haematologica. 2025-02-06
• Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
  Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen
  Bone Marrow Transplantation. 2025-01-01

Abstracts/Posters

• Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
  Adam Waxman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study. 
  2019 ASCO Annual Meeting - 6/1/2019
• Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all